Akut Respiratuar Distres Sendromunda Kişiselleştirilmiş Tıbba Doğru
Özet
Akut Respiratuar Distres Sendromu (ARDS), yüksek mortalite oranına sahip, etiyolojik ve biyokimyasal açıdan heterojen bir kritik hastalıktır. Geleneksel tedavilerin yetersiz kalması, hastalığın alt fenotiplerinin doğru tanımlanmasını ve kişiselleştirilmiş tıp yaklaşımlarını zorunlu kılmıştır. ARDS, Berlin tanımlamasına göre hipoksemi ciddiyetine göre sınıflandırılsa da, bu durum her zaman klinik sonlanımlarla doğrudan ilişkili değildir. Patofizyolojik olarak alveolo-kapiller membran hasarı ve enflamasyonla karakterize olan hastalıkta, erken dönemde yaygın alveolar hasar, geç dönemde ise bazı hastalarda fibroproliferasyon gözlenir. Klinik çalışmalarda genel yaklaşımların %95'inin başarısız olması, "heterojen tedavi etkisi" kavramını ön plana çıkarmıştır. Latent Sınıf Analizi gibi yöntemlerle "hiperenflamatuar" ve "hipoenflamatuar" gibi biyolojik subfenotipler tanımlanmış, bu grupların PEEP stratejilerine ve sıvı tedavilerine farklı yanıtlar verdiği saptanmıştır. Günümüzde akciğer koruyucu ventilasyon ve yüzüstü pozisyonlama temel tedavi stratejileridir. Kişiselleştirilmiş tıp kapsamında omik analizleri, biyobelirteçler (Ang-2, sRAGE, IL-8 vb.) ve yapay zeka entegrasyonu, doğru hastaya doğru zamanda müdahale edilmesini hedeflemektedir. Gelecekte, genetik ve moleküler düzeydeki bu verilerin yatak başı uygulamalara dönüştürülmesiyle ARDS prognozunda anlamlı iyileşmeler beklenmektedir.
Acute Respiratory Distress Syndrome (ARDS) is a critical condition characterized by high mortality and significant heterogeneity in its etiological and biochemical presentation. The failure of traditional, one-size-fits-all treatments has highlighted the necessity for identifying specific subphenotypes and adopting personalized medicine approaches. While ARDS is classified by the severity of hypoxemia according to the Berlin Definition, this classification does not always correlate directly with clinical outcomes. Pathophysiological features include alveolar-capillary membrane damage and inflammation, leading to diffuse alveolar damage in the acute phase and potential fibroproliferation in later stages. The 95% failure rate of general clinical trials underscores the "heterogeneity of treatment effect". Advanced methods like Latent Class Analysis have identified "hyperinflammatory" and "hypoinflammatory" biological subphenotypes, which respond differently to PEEP strategies and fluid management. Currently, lung-protective ventilation and prone positioning remain the cornerstones of treatment. Personalized medicine aims to leverage omics analysis, biomarkers (such as Ang-2, sRAGE, and IL-8), and AI integration to provide targeted interventions. The future of ARDS management lies in translating these genetic and molecular insights into bedside applications to improve patient prognosis.
Referanslar
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669
Bos LDJ, Artigas A, Constantin JM, et al. Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. Eur Respir Rev. 2021;30(159):200317. doi:10.1183/16000617.0317-2020
Wu AC, Kiley JP, Noel PJ, et al. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. Am J Respir Crit Care Med. 2018;198(12):e116-e136. doi:10.1164/rccm.201810-1895ST
Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory distress in adults. Lancet. 1967;2(7511):319-323. doi:10.1016/s0140-6736(67)90168-7
Wildi K, Livingstone S, Palmieri C, et al. The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine? [published correction appears in J Intensive Care. 2021;9(1):22]. J Intensive Care. 2021;9(1):14. doi:10.1186/s40560-021-00528-w
Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries JAMA. 2016;315(8):788-800. doi:10.1001/jama.2016.0291.
Samanta RJ, Summers C. Translational Research in Intensive Care Unit: Novel Approaches for Drug Development and Personalized Medicine. Semin Respir Crit Care Med. 2019;40(5):687-698. doi:10.1055/s-0039-1698407
Herridge MS, Moss M, Hough CL, et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016;42(5):725-738. doi:10.1007/s00134-016-4321-8
Spadaro S, Park M, Turrini C, et al. Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine. J Inflamm (Lond). 2019;16:1. doi:10.1186/s12950-018-0202-y
Marshall RP, Bellingan G, Webb S, et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med. 2000;162(5):1783-1788. doi:10.1164/ajrccm.162.5.2001061
Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-1684. doi:10.1056/NEJMoa051693
Gibelin A, Parrot A, Maitre B, et al. Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition. Intensive Care Med. 2016;42(2):164-172. doi:10.1007/s00134-015-4064-y
Jouanna J, Magdeliane C. (2018). Hippokrates Külliyatı (Nur Nirven, Çev. Ed.). İstanbul: Pinhan Yayıncılık.
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620. doi:10.1016/S2213-2600(14)70097-9
Vincent JL. The coming era of precision medicine for intensive care. Crit Care. 2017;21(Suppl 3):314. Published 2017 Dec 28. doi:10.1186/s13054-017-1910-z
Girbes ARJ, de Grooth HJ. Time to stop randomized and large pragmatic trials for intensive care medicine syndromes: the case of sepsis and acute respiratory distress syndrome. J Thorac Dis. 2020;12(Suppl 1):S101-S109. doi:10.21037/jtd.2019.10.36
Khan YA, Fan E, Ferguson ND. Precision Medicine and Heterogeneity of Treatment Effect in Therapies for ARDS. Chest. 2021;160(5):1729-1738. doi:10.1016/j.chest.2021.07.009
Beitler JR, Thompson BT, Baron RM, et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir Med. 2021;S2213-2600(21)00157-0. doi:10.1016/S2213-2600(21)00157-0
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100. doi:10.1038/clpt.2009.68.
Israel E, Denlinger LC, Bacharier LB, et al. PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. J Allergy Clin Immunol. 2021;147(5):1594-1601. doi:10.1016/j.jaci.2021.01.037
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436
National Institutes of Health. COVID-19 therapeutics prioritized for testing in clinical trials. Nov 9, 2020. https://www.nih.gov/ research-training/medical-research-initiatives/activ/covid-19- therapeutics-prioritized-testing-clinical-trials (accessed June 24, 2021).
Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020;17(7):879-891. doi:10.1513/AnnalsATS.202003-192SD
Jabaudon M, Blondonnet R, Audard J, et al. Recent directions in personalised acute respiratory distress syndrome medicine. Anaesth Crit Care Pain Med. 2018;37(3):251-258. doi:10.1016/j.accpm.2017.08.006
Meyer NJ, Calfee CS. Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. Lancet Respir Med. 2017;5(6):512-523. doi:10.1016/S2213-2600(17)30187-X
Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351(4):327-336. doi:10.1056/NEJMoa032193
Zhao Z, Wickersham N, Kangelaris KN, et al. External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome. Intensive Care Med. 2017;43(8):1123-1131. doi:10.1007/s00134-017-4854-5
National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575. doi:10.1056/NEJMoa062200
Bos LD, Schouten LR, van Vught LA, et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017;72(10):876-883. doi:10.1136/thoraxjnl-2016-209719
Bos LDJ, Scicluna BP, Ong DSY, et al. Understanding Heterogeneity in Biologic Phenotypes of Acute Respiratory Distress Syndrome by Leukocyte Expression Profiles. Am J Respir Crit Care Med. 2019;200(1):42-50. doi:10.1164/rccm.201809-1808OC
Villar J, Pérez-Méndez L, Blanco J, et al. A universal definition of ARDS: the PaO2/FiO2 ratio under a standard ventilatory setting--a prospective, multicenter validation study. Intensive Care Med. 2013;39(4):583-592. doi:10.1007/s00134-012-2803-x
Matthay MA, Arabi YM, Siegel ER, et al. Phenotypes and personalized medicine in the acute respiratory distress syndrome. Intensive Care Med. 2020;46(12):2136-2152. doi:10.1007/s00134-020-06296-9
Yehya N, Hodgson CL, Amato MBP, et al. Response to Ventilator Adjustments for Predicting Acute Respiratory Distress Syndrome Mortality. Driving Pressure versus Oxygenation. Ann Am Thorac Soc. 2021;18(5):857-864. doi:10.1513/AnnalsATS.202007-862OC
Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010;303(9):865-873. doi:10.1001/jama.2010.218
Cavalcanti AB, Suzumura É, Laranjeira LN, et al. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2017;318(14):1335-1345. doi:10.1001/jama.2017.14171
Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi:10.1056/NEJMoa1005372
Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168. doi:10.1056/NEJMoa1214103
Reilly JP, Calfee CS, Christie JD. Acute Respiratory Distress Syndrome Phenotypes. Semin Respir Crit Care Med. 2019;40(1):19-30. doi:10.1055/s-0039-1684049
Tejera P, Meyer NJ, Chen F, et al. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet. 2012;49(11):671-680. doi:10.1136/jmedgenet-2012-100972
Zampieri FG, Costa EL, Iwashyna TJ, et al. Heterogeneous effects of alveolar recruitment in acute respiratory distress syndrome: a machine learning reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial. Br J Anaesth. 2019;123(1):88-95. doi:10.1016/j.bja.2019.02.026
Croce MA, Fabian TC, Davis KA, Gavin TJ. Early and late acute respiratory distress syndrome: two distinct clinical entities. J Trauma. 1999;46(3):361-368. doi:10.1097/00005373-199903000-00001
Reilly JP, Bellamy S, Shashaty MG, et al. Heterogeneous phenotypes of acute respiratory distress syndrome after major trauma. Ann Am Thorac Soc. 2014;11(5):728-736. doi:10.1513/AnnalsATS.201308-280OC
Zhang R, Wang Z, Tejera P, et al. Late-onset moderate to severe acute respiratory distress syndrome is associated with shorter survival and higher mortality: a two-stage association study. Intensive Care Med. 2017;43(3):399-407. doi:10.1007/s00134-016-4638-3
Puybasset L, Cluzel P, Gusman P, et al. Regional distribution of gas and tissue in acute respiratory distress syndrome. I. Consequences for lung morphology. CT Scan ARDS Study Group. Intensive Care Med. 2000;26(7):857-869. doi:10.1007/s001340051274
Constantin JM, Jabaudon M, Lefrant JY, et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir Med. 2019;7(10):870-880. doi:10.1016/S2213-2600(19)30138-9
Warren MA, Zhao Z, Koyama T, et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax. 2018;73(9):840-846. doi:10.1136/thoraxjnl-2017-211280
Kotok D, Yang L, Evankovich JW, et al. The evolution of radiographic edema in ARDS and its association with clinical outcomes: A prospective cohort study in adult patients. J Crit Care. 2020;56:222-228. doi:10.1016/j.jcrc.2020.01.012
de Blic J, Midulla F, Barbato A, et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. Eur Respir J. 2000;15(1):217-231. doi:10.1183/09031936.00.15121700
McNeil JB, Shaver CM, Kerchberger VE, et al. Novel Method for Noninvasive Sampling of the Distal Airspace in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018;197(8):1027-1035. doi:10.1164/rccm.201707-1474OC
Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy Am J Respir Crit Care Med. 2017;195(3):331-338. doi:10.1164/rccm.201603-0645OC
Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6(9):691-698. doi:10.1016/S2213-2600(18)30177-2
Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018;44(11):1859-1869. doi:10.1007/s00134-018-5378-3
Sinha P, Delucchi KL, McAuley DF, O'Kane CM, Matthay MA, Calfee CS. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247-257. doi:10.1016/S2213-2600(19)30369-8
Simonis FD, de Iudicibus G, Cremer OL, et al. Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients. Ann Transl Med. 2018;6(2):24. doi:10.21037/atm.2017.12.25
Kitsios GD, Yang L, Manatakis DV, et al. Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at Risk for Acute Respiratory Distress Syndrome. Crit Care Med. 2019;47(12):1724-1734. doi:10.1097/CCM.0000000000004018
Sinha P, Churpek MM, Calfee CS. Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. Am J Respir Crit Care Med. 2020;202(7):996-1004. doi:10.1164/rccm.202002-0347OC
Cioccari L, Luethi N, Masoodi M. Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine. Front Immunol. 2020;11:599853. doi:10.3389/fimmu.2020.599853
Jones TK, Feng R, Kerchberger VE, et al. Plasma sRAGE Acts as a Genetically Regulated Causal Intermediate in Sepsis-associated Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020;201(1):47-56. doi:10.1164/rccm.201810-2033OC
Reilly JP, Wang F, Jones TK, et al. Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis. Intensive Care Med. 2018;44(11):1849-1858. doi:10.1007/s00134-018-5328-0
Christie JD, Wurfel MM, Feng R, et al. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS One. 2012;7(1):e28268. doi:10.1371/journal.pone.0028268
Kerchberger VE, Bastarache JA, Shaver CM, et al. Haptoglobin-2 variant increases susceptibility to acute respiratory distress syndrome during sepsis. JCI Insight. 2019;4(21):e131206. doi:10.1172/jci.insight.131206
Samanta RJ, Summers C. Translational Research in Intensive Care Unit: Novel Approaches for Drug Development and Personalized Medicine. Semin Respir Crit Care Med. 2019;40(5):687-698. doi:10.1055/s-0039-1698407
Sweeney TE, Thomas NJ, Howrylak JA, et al. Multicohort Analysis of Whole-Blood Gene Expression Data Does Not Form a Robust Diagnostic for Acute Respiratory Distress Syndrome. Crit Care Med. 2018;46(2):244-251. doi:10.1097/CCM.0000000000002839
Kangelaris KN, Prakash A, Liu KD, et al. Increased expression of neutrophil-related genes in patients with early sepsis-induced ARDS. Am J Physiol Lung Cell Mol Physiol. 2015;308(11):L1102-L1113. doi:10.1152/ajplung.00380.2014
Bime C, Pouladi N, Sammani S, et al. Genome-Wide Association Study in African Americans with Acute Respiratory Distress Syndrome Identifies the Selectin P Ligand Gene as a Risk Factor. Am J Respir Crit Care Med. 2018;197(11):1421-1432. doi:10.1164/rccm.201705-0961OC
Howrylak JA, Dolinay T, Lucht L, et al. Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics. 2009;37(2):133-139. doi:10.1152/physiolgenomics.90275.2008
Kovach MA, Stringer KA, Bunting R, et al. Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome. Respir Res. 2015;16(1):29. doi:10.1186/s12931-015-0190-x
Chen X, Shan Q, Jiang L, et al. Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. Biochem Biophys Res Commun. 2013;441(1):1-6. doi:10.1016/j.bbrc.2013.09.027
Bhargava M, Becker TL, Viken KJ, et al. Proteomic profiles in acute respiratory distress syndrome differentiates survivors from non-survivors. PLoS One. 2014;9(10):e109713. Published 2014 Oct 7. doi:10.1371/journal.pone.0109713
Williams TJ, Peck MJ. Role of prostaglandin-mediated vasodilatation in inflammation. Nature. 1977;270(5637):530-532. doi:10.1038/270530a0
Evans CR, Karnovsky A, Kovach MA, et al. Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J Proteome Res. 2014;13(2):640-649. doi:10.1021/pr4007624
Bos LD, Weda H, Wang Y, et al. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome. Eur Respir J. 2014;44(1):188-197. doi:10.1183/09031936.00005614
Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016;62(7):817-823. doi:10.1093/cid/civ1214
Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016;1(10):16113. doi:10.1038/nmicrobiol.2016.113
Wong JJM, Leong JY, Lee JH, et al. Insights into the immuno-pathogenesis of acute respiratory distress syndrome. Ann Transl Med. 2019;7(19):504. doi:10.21037/atm.2019.09.28
Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4(3):a006049. Published 2012 Mar 1. doi:10.1101/cshperspect.a006049
Snelgrove RJ, Goulding J, Didierlaurent AM, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. 2008;9(9):1074-1083. doi:10.1038/ni.1637
Soltys J, Bonfield T, Chmiel J, et al. Functional IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol. 2002;168(4):1903-1910. doi:10.4049/jimmunol.168.4.1903
Jiang Z, Zhou Q, Gu C, Li D, Zhu L. Depletion of circulating monocytes suppresses IL-17 and HMGB1 expression in mice with LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2017;312(2):L231-L242. doi:10.1152/ajplung.00389.2016.
Tu GW, Shi Y, Zheng YJ, et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J Transl Med. 2017;15(1):181. doi:10.1186/s12967-017-1284-7
Keck T, Balcom JH 4th, Fernández-del Castillo C, et al. Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. Gastroenterology. 2002;122(1):188-201. doi:10.1053/gast.2002.30348
Porto BN, Stein RT. Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?. Front Immunol. 2016;7:311. Published 2016 Aug 15. doi:10.3389/fimmu.2016.00311
Garnier M, Gibelin A, Mailleux AA, et al. Macrophage Polarization Favors Epithelial Repair During Acute Respiratory Distress Syndrome. Crit Care Med. 2018;46(7):e692-e701. doi:10.1097/CCM.0000000000003150
Constantin JM, Godet T, Jabaudon M. Understanding Macrophages in Acute Respiratory Distress Syndrome: From Pathophysiology to Precision Medicine. Crit Care Med. 2018;46(7):1207-1208. doi:10.1097/CCM.0000000000003175
Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-2196. doi:10.1056/NEJMoa1503326
Levitt JE, Bedi H, Calfee CS, Gould MK, Matthay MA. Identification of early acute lung injury at initial evaluation in an acute care setting prior to the onset of respiratory failure. Chest. 2009;135(4):936-943. doi:10.1378/chest.08-2346
Mauri T, Lazzeri M, Bellani G, Zanella A, Grasselli G. Respiratory mechanics to understand ARDS and guide mechanical ventilation. Physiol Meas. 2017;38(12):R280-H303. Published 2017 Nov 30. doi:10.1088/1361-6579/aa9052
Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med. 2013;368(9):795-805. doi:10.1056/NEJMoa1215554 54.
Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. N Engl J Med. 2013;368(9):806-813. doi:10.1056/NEJMoa1215716
Pelosi P, D'Onofrio D, Chiumello D, et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J Suppl. 2003;42:48s-56s. doi:10.1183/09031936.03.00420803
Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med. 2006;354(17):1775-1786. doi:10.1056/NEJMoa052052
Gattinoni L, Pesenti A. The concept of "baby lung". Intensive Care Med. 2005;31(6):776-784. doi:10.1007/s00134-005-2627-z
Amato MB, Barbas CS, Medeiros DM, et al. Beneficial effects of the "open lung approach" with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med. 1995;152(6 Pt 1):1835-1846. doi:10.1164/ajrccm.152.6.8520744
Grasso S, Stripoli T, De Michele M, et al. ARDSnet ventilatory protocol and alveolar hyperinflation: role of positive end-expiratory pressure. Am J Respir Crit Care Med. 2007;176(8):761-767. doi:10.1164/rccm.200702-193OC
Pesenti A, Pelosi P, Rossi N, et al. The effects of positive end-expiratory pressure on respiratory resistance in patients with the adult respiratory distress syndrome and in normal anesthetized subjects. Am Rev Respir Dis. 1991;144(1):101-107. doi:10.1164/ajrccm/144.1.101
Maggiore SM, Richard JC, Brochard L. What has been learnt from P/V curves in patients with acute lung injury/acute respiratory distress syndrome. Eur Respir J Suppl. 2003;42:22s-26s. doi:10.1183/09031936.03.00004204
Talmor D, Sarge T, Malhotra A, et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med. 2008;359(20):2095-2104. doi:10.1056/NEJMoa0708638
Silva PL, Pelosi P, Rocco PRM. Personalized pharmacological therapy for ARDS: a light at the end of the tunnel. Expert Opin Investig Drugs. 2020;29(1):49-61. doi:10.1080/13543784.2020.1699531
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276. doi:10.1016/S2213-2600(19)30417-5
Sun S, Liu D, Zhang H, et al. Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: A meta-analysis. Exp Ther Med. 2019;18(6):4637-4644. doi:10.3892/etm.2019.8167
Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23(1):99. doi:10.1186/s13054-019-2395-8
Donnelly SC, MacGregor I, Zamani A, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151(5):1428-1433. doi:10.1164/ajrccm.151.5.7735596
Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32(8):1695-1702. doi:10.1097/01.ccm.0000133332.48386.85
Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med. 1996;334(22):1417-1421. doi:10.1056/NEJM199605303342201
Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351(9):884-892. doi:10.1056/NEJMoa033181
Matera MG, Rogliani P, Bianco A, Cazzola M. Pharmacological management of adult patients with acute respiratory distress syndrome. Expert Opin Pharmacother. 2020;21(17):2169-2183. doi:10.1080/14656566.2020.1801636
Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. JAMA. 2016;315(22):2406-2414. doi:10.1001/jama.2016.6330
Schuster DP, Metzler M, Opal S, et al. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med. 2003;31(6):1612-1619. doi:10.1097/01.CCM.0000063267.79824.DB
Gonzalez H, Horie S, Laffey JG. Emerging cellular and pharmacologic therapies for acute respiratory distress syndrome. Curr Opin Crit Care. 2021;27(1):20-28. doi:10.1097/MCC.0000000000000784
McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017;5(6):484-491. doi:10.1016/S2213-2600(17)30171-6
Silva PL, Rocco PR, Pelosi P. FG-4497: a new target for acute respiratory distress syndrome?. Expert Rev Respir Med. 2015;9(4):405-409. doi:10.1586/17476348.2015.1065181
Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi:10.1056/NEJMoa1005372
Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019;380(21):1997-2008. doi:10.1056/NEJMoa1901686
Ho ATN, Patolia S, Guervilly C. Neuromuscular blockade in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. J Intensive Care. 2020;8:12. Published 2020 Jan 28. doi:10.1186/s40560-020-0431-z
Fowler AA 3rd, Truwit JD, Hite RD, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322(13):1261-1270. doi:10.1001/jama.2019.11825
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde AA, Brower RG, et al. Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients. N Engl J Med. 2019;381(26):2529-2540. doi:10.1056/NEJMoa1911124
Lu X, Ma Y, He J, et al. N-acetylcysteine for adults with acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. Hong Kong J Emerg Med. 2019;26(5):288–298.
Xu Q, Yan Q, Chen S. Ulinastatin is effective in reducing mortality for critically ill patients with sepsis: a causal mediation analysis. Sci Rep. 2018;8(1):14360. doi:10.1038/s41598-018-32533-9
Ji M, Chen T, Wang B, et al. Effects of ulinastatin combined with mechanical ventilation on oxygen metabolism, inflammation and stress response and antioxidant capacity of ARDS. Exp Ther Med. 2018;15(6):4665-4670. doi:10.3892/etm.2018.6012
Zhang X, Zhu Z, Jiao W, Liu W, Liu F, Zhu X. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):196. Published 2019 Nov 4. doi:10.1186/s12890-019-0968-6
Horie S, McNicholas B, Rezoagli E, et al. Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med. 2020;46(12):2265-2283. doi:10.1007/s00134-020-06141-z
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154-162. doi:10.1016/S2213-2600(18)30418-1
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11(2):216-228. Published 2020 Mar 9. doi:10.14336/AD.2020.0228
Islam D, Huang Y, Fanelli V, et al. Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury. Am J Respir Crit Care Med. 2019;199(10):1214-1224. doi:10.1164/rccm.201802-0356OC
Goligher EC, Amato MBP, Slutsky AS. Applying Precision Medicine to Trial Design Using Physiology. Extracorporeal CO2 Removal for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;196(5):558-568. doi:10.1164/rccm.201701-0248CP
Tonelli AR, Zein J, Adams J, Ioannidis JP. Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. Intensive Care Med. 2014;40(6):769-787. doi:10.1007/s00134-014-3272-1
Krumm ZA, Lloyd GM, Francis CP, et al. Precision therapeutic targets for COVID-19. Virol J. 2021;18(1):66. doi:10.1186/s12985-021-01526-y
Waterer GW, Rello J. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. Infect Dis Ther. 2020;9(4):701-705. doi:10.1007/s40121-020-00338-x
Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med. 2020;8(12):1209-1218. doi:10.1016/S2213-2600(20)30366-0
Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. doi:10.1186/s13054-017-1823-x
